panobinostat (Farydak)

Indications

• treatment of multiple myeloma in patients who had received at least 2 previous treatments, including bortezomib & a biological response modifier
  • for use in combination with bortezomib & dexamethasone [NGC, NICE]

Dosage

Capsules: 10 mg, 15 mg, 20 mg

Adverse effects

• most common
  • diarrhea, fatigue, nausea, peripheral edema, anorexia, fever, vomiting, weakness
• most common laboratory abnormalities:
  • hypophosphatemia, hypokalemia, hyponatremia, increased serum creatinine, thrombocytopenia, leukopenia, anemia
• hemorrhage: GI bleed, pulmonary hemorrhage
• hepatotoxicity
• boxed warning
  • severe diarrhea
  • severe & fatal cardiac events, arrhythmias & ECG changes

Mechanism of action

• non-specific histone deacetylase inhibitor

More general terms

• heterocyclic compound, 2 rings
• aromatic compound
• amine
• alkene; olefin
• hydroxamic acid
• histone decetylase inhibitor
• antineoplastic agent (chemotherapeutic agent)

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918837
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23725423
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=57369374